Unichem Laboratories Limited (UNICHEMLAB.BO)
INR 587.6
(-2.16%)
INR 587.6
(-2.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 742.35 Million INR | 47.75% |
| 2022 | -456.06 Million INR | -139.62% |
| 2021 | 1.18 Billion INR | -5.12% |
| 2020 | 1.41 Billion INR | 775.78% |
| 2019 | 404.93 Million INR | 585.26% |
| 2018 | 149.18 Million INR | 102.72% |
| 2017 | -710.16 Million INR | -127.34% |
| 2016 | -358.89 Million INR | -119.5% |
| 2015 | 1.63 Billion INR | 47.4% |
| 2014 | 1.01 Billion INR | -39.65% |
| 2013 | 1.77 Billion INR | 16.79% |
| 2012 | 1.71 Billion INR | 38.09% |
| 2011 | 1.24 Billion INR | -21.5% |
| 2010 | 1.58 Billion INR | -10.79% |
| 2009 | 1.77 Billion INR | 17.03% |
| 2008 | 1.51 Billion INR | 62.98% |
| 2007 | 930.55 Million INR | -9.93% |
| 2006 | 1.03 Billion INR | 11.45% |
| 2005 | 926.99 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 434.98 Million INR | 146.22% |
| 2023 Q4 | -1 Billion INR | -363.07% |
| 2023 FY | - INR | 47.75% |
| 2023 Q1 | 366.48 Million INR | 269.41% |
| 2023 Q2 | 142.98 Million INR | -60.98% |
| 2023 Q3 | 381.14 Million INR | 166.57% |
| 2022 Q4 | -216.32 Million INR | 16.29% |
| 2022 Q1 | 74.51 Million INR | -90.68% |
| 2022 Q2 | -85.36 Million INR | -214.56% |
| 2022 Q3 | -258.41 Million INR | -202.72% |
| 2022 FY | - INR | -139.62% |
| 2021 Q3 | 193.57 Million INR | 113.53% |
| 2021 FY | - INR | -5.12% |
| 2021 Q4 | 799.92 Million INR | 313.23% |
| 2021 Q2 | 90.65 Million INR | -35.67% |
| 2021 Q1 | 140.91 Million INR | -5.26% |
| 2020 Q2 | 399.04 Million INR | 38.41% |
| 2020 Q3 | 455.77 Million INR | 14.22% |
| 2020 Q4 | 148.74 Million INR | -67.36% |
| 2020 Q1 | 288.29 Million INR | 7635.15% |
| 2020 FY | - INR | 775.78% |
| 2019 Q4 | -3.82 Million INR | -104.56% |
| 2019 Q3 | 83.9 Million INR | 543.39% |
| 2019 Q2 | 13.04 Million INR | -77.57% |
| 2019 Q1 | 58.14 Million INR | -81.88% |
| 2019 FY | - INR | 585.26% |
| 2018 FY | - INR | 102.72% |
| 2018 Q4 | 320.84 Million INR | 282.77% |
| 2018 Q3 | 83.82 Million INR | 136.6% |
| 2018 Q2 | -229.04 Million INR | -48.03% |
| 2018 Q1 | -154.72 Million INR | -373.11% |
| 2017 FY | - INR | -127.34% |
| 2017 Q4 | 56.65 Million INR | 0.0% |
| 2016 Q4 | 2.11 Billion INR | 0.0% |
| 2016 FY | - INR | -119.5% |
| 2015 FY | - INR | 47.4% |
| 2014 FY | - INR | -39.65% |
| 2013 FY | - INR | 16.79% |
| 2012 FY | - INR | 38.09% |
| 2011 FY | - INR | -21.5% |
| 2010 FY | - INR | -10.79% |
| 2009 FY | - INR | 17.03% |
| 2008 FY | - INR | 62.98% |
| 2007 FY | - INR | -9.93% |
| 2006 FY | - INR | 11.45% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 92.281% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.799% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 89.183% |
| Granules India Limited | 8.6 Billion INR | 91.372% |
| Indoco Remedies Limited | 2.64 Billion INR | 71.955% |
| Achyut Healthcare Limited | 524 Thousand INR | -141570.992% |
| Ajanta Pharma Limited | 12.56 Billion INR | 94.092% |
| Alkem Laboratories Limited | 24.19 Billion INR | 96.932% |
| Alpa Laboratories Limited | 86.12 Million INR | -761.932% |
| Brooks Laboratories Limited | 41.72 Million INR | -1679.036% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 68.502% |
| Bajaj HealthCare Limited | 444.51 Million INR | -67.003% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 49.808% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.159% |
| Eris Lifesciences Limited | 6.98 Billion INR | 89.374% |
| FDC Limited | 4.4 Billion INR | 83.135% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 93.456% |
| Gufic Biosciences Limited | 1.48 Billion INR | 49.857% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 89.181% |
| Ipca Laboratories Limited | 13.29 Billion INR | 94.418% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -129.505% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 997.356% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1240.682% |
| Laurus Labs Limited | 8 Billion INR | 90.728% |
| Lupin Limited | 36.96 Billion INR | 97.992% |
| Mankind Pharma Limited | 28.09 Billion INR | 97.358% |
| Medicamen Biotech Limited | 245.66 Million INR | -202.188% |
| Medico Remedies Limited | 150.37 Million INR | -393.66% |
| Megasoft Limited | 284.73 Million INR | -160.722% |
| NATCO Pharma Limited | 18.79 Billion INR | 96.05% |
| Piramal Pharma Limited | 13.05 Billion INR | 94.314% |
| RPG Life Sciences Limited | 1.28 Billion INR | 42.071% |
| Sigachi Industries Limited | 883.39 Million INR | 15.966% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.463% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 84.128% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -72.53% |
| Wanbury Limited | 985.49 Million INR | 24.671% |
| Windlas Biotech Limited | 781.72 Million INR | 5.036% |
| ZIM Laboratories Limited | 462.09 Million INR | -60.649% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.68% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 119.896% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.081% |
| Hester Biosciences Limited | 539.47 Million INR | -37.608% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 75.373% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -8.764% |
| Bal Pharma Limited | 345.59 Million INR | -114.807% |
| Strides Pharma Science Limited | 3.76 Billion INR | 80.281% |
| Venus Remedies Limited | 711.8 Million INR | -4.293% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 81.011% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 52.528% |
| Shilpa Medicare Limited | 2.58 Billion INR | 71.315% |
| Aarti Drugs Limited | 3.24 Billion INR | 77.149% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 71.52% |
| Suven Life Sciences Limited | -992.78 Million INR | 174.775% |
| Ind-Swift Limited | 1.06 Billion INR | 30.3% |
| Valiant Laboratories Limited | 12.73 Million INR | -5727.428% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 92.047% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 126.307% |
| Themis Medicare Limited | 562.6 Million INR | -31.949% |
| Hikal Limited | 2.69 Billion INR | 72.426% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 97.88% |
| Sequent Scientific Limited | 549.8 Million INR | -35.023% |
| Novartis India Limited | 1.26 Billion INR | 41.515% |
| Wockhardt Limited | 1.08 Billion INR | 31.263% |
| Jubilant Pharmova Limited | 8 Billion INR | 90.728% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -5583.326% |
| Neuland Laboratories Limited | 4.74 Billion INR | 84.365% |
| Morepen Laboratories Limited | 1.72 Billion INR | 56.989% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -158.278% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -324.334% |